MLANA and metastatic melanoma: Based on these arguments and thanks to an original technique for sorting these specific T lymphocytes [16], we set up a unique phase I/II clinical trial called MELSORT (NCT02424916, https://clinicaltrials.gov), in which Melan-A and MELOE-1 specific T cells were infused to 6 metastatic melanoma patients.